CEPHEID (CPHD) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Cepheid; Are Shareholders Getting a Fair Price?

SAN DIEGO, Sept. 6, 2016

Additional Information:
Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical and non-clinical markets.

On September 6, 2016, Cepheid announced it had signed a definitive merger agreement with Danaher. Under the terms of the agreement, Cepheid stockholders will receive $53.00 per share in cash.

The investigation concerns whether the Cepheid board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Cepheid shares of common stock. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration. The deal may undervalue the Company resulting in a loss for many long term shareholders. For example, on July 20, 2015, Cepheid traded at $63.69.

If you are a shareholder of Cepheid  and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If emailing, please include a phone number where you can be reached.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com